Acute Respiratory Distress Syndrome (ARDS) is a serious and often life-threatening condition, characterised by refractory hypoxaemia, for which there is no effective licensed pharmacotherapy. ARDS affects more than 10% of all patients admitted to ICU, of whom 35-55% will not survive to leave hospital. Even survivorship carries a significant morbidity burden, and the economic cost of the condition to individuals, healthcare budgets and society is considerable. Patients with ARDS have prolonged hospital admissions, and frequently develop complications such as nosocomial infections.
ARDS affects more than 10% of all patients admitted to ICU, of whom 35-55% will not survive to leave hospital
Data suggest that ARDS survivors have reduced exercise capacity, and often (>50%) endure marked physical and neurocognitive deficits as a consequence of their initial illness. A significant proportion of ARDS survivors never return to their premorbid occupation, and there is evidence to suggest that ARDS significantly impacts family members, both in terms of mental health and economic productivity, in the five years after diagnosis.
Our work aims to understand the cellular mechanisms underlying acute lung inflammation so we can develop effective therapies for this debilitating condition.